R. E. Bachelder, A. Crago, J. Chung, M. A. Wendt, L. M. Shaw et al., Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells, Cancer Res, vol.61, pp.5736-5776, 2001.

R. E. Bachelder, M. A. Wendt, and A. M. Mercurio, , 2002.

D. O. Bates, T. G. Cui, J. M. Doughty, M. Winkler, M. Sugiono et al., , 2002.

, VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma, Cancer Res, vol.62, pp.4123-4154

D. O. Bates, P. P. Macmillan, J. G. Manjaly, Y. Qiu, S. J. Hudson et al., The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are downregulated in pre-eclamptic placentae at term, Clin Sci, vol.110, pp.575-85, 2006.

P. Carmeliet and R. K. Jain, Angiogenesis in cancer and other diseases, Nature, vol.407, pp.249-57, 2000.

R. Catena, V. Muniz-medina, B. Moralejo, B. Javierre, C. J. Best et al., , 2007.

, Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis, Int J Cancer, vol.120, pp.2096-109

N. Cheung, M. P. Wong, S. T. Yuen, S. Y. Leung, and L. P. Chung, Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon, Hum Pathol, vol.29, pp.910-914, 1998.

C. D. Cohen, P. P. Doran, S. M. Blattner, M. Merkle, G. Q. Wang et al., Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor, J Am Soc Nephrol, vol.16, pp.1958-65, 2005.

J. N. Davis, K. J. Wojno, S. Daignault, M. D. Hofer, R. Kuefer et al., Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer, Cancer Res, vol.66, pp.11897-906, 2006.

A. P. Elias and S. Dias, Microenvironment Changes (in pH) Affect VEGF Alternative Splicing, Cancer Microenviron, vol.1, pp.131-140, 2008.

N. Ferrara, H. P. Gerber, and J. Lecouter, The biology of VEGF and its receptors, Nat Med, vol.9, pp.669-76, 2003.

J. Folkman, Angiogenesis: an organizing principle for drug discovery?, Nat Rev Drug Discov, vol.6, pp.273-86, 2007.

G. Fontemaggi, S. Dell'orso, D. Trisciuoglio, T. Shay, E. Melucci et al., The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neoangiogenesis, Nat Struct Mol Biol, vol.16, pp.1086-93, 2009.

H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth et al., , 2004.

, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, vol.350, pp.2335-2377

H. I. Hurwitz, L. Fehrenbacher, J. D. Hainsworth, W. Heim, J. Berlin et al., , 2005.

, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, vol.23, pp.3502-3510

S. X. Jiang, M. Sheldrick, A. Desbois, J. Slinn, and S. T. Hou, Neuropilin-1 is a direct target of the transcription factor E2F1 during cerebral ischemia-induced neuronal death in vivo, Mol Cell Biol, vol.27, pp.1696-705, 2007.

H. Kawamura, X. Li, S. J. Harper, D. O. Bates, and L. Claesson-welsh, Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity, Cancer Res, vol.68, pp.4683-92, 2008.

M. R. Ladomery, S. J. Harper, and D. O. Bates, Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm, Cancer Lett, vol.249, pp.133-175, 2007.

S. Lantuejoul, B. Constantin, H. Drabkin, C. Brambilla, J. Roche et al., , 2003.

, Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1

, NP2 in preinvasive bronchial lesions, lung tumours, and cell lines, J Pathol, vol.200, pp.336-383

G. Merdzhanova, V. Edmond, D. Seranno, S. Van-den-broeck, A. Corcos et al., E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35, Cell Death Differ, vol.15, pp.1815-1838, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00360967

D. G. Nowak, J. Woolard, E. M. Amin, O. Konopatskaya, M. A. Saleem et al., , 2008.

, Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors, J Cell Sci, vol.121, pp.3487-95

D. G. Nowak, E. M. Amin, E. S. Rennel, C. Hoareau-aveilla, M. Gammons et al., Regulation of vascular endothelial growth factor (VEGF) splicing from proangiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis, J Biol Chem, vol.285, pp.5532-5572, 2010.

S. Polager and D. Ginsberg, E2F -at the crossroads of life and death, Trends Cell Biol, vol.18, pp.528-563, 2008.

R. O. Pritchard-jones, D. B. Dunn, Y. Qiu, A. H. Varey, A. Orlando et al., , 2007.

, Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma, Br J Cancer, vol.97, pp.223-253

G. Qin, R. Kishore, C. M. Dolan, M. Silver, A. Wecker et al., Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF, 2006.

, Proc Natl Acad Sci U S A, vol.103, pp.11015-11035

J. Rak, Y. Mitsuhashi, L. Bayko, J. Filmus, S. Shirasawa et al., Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis, Cancer Res, vol.55, pp.4575-80, 1995.

E. Rennel, W. E. Guan, H. Schuler, Y. Leenders, W. Woolard et al., The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice, Br J Cancer, vol.98, pp.1250-1257, 2008.

C. J. Robinson and S. E. Stringer, The splice variants of vascular endothelial growth factor (VEGF) and their receptors, J Cell Sci, vol.114, pp.853-65, 2001.

C. Salon, B. Eymin, O. Micheau, L. Chaperot, J. Plumas et al., , pp.2-3, 2006.

, induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short), Cell Death Differ, vol.13, pp.260-72

C. Salon, G. Merdzhanova, C. Brambilla, E. Brambilla, S. Gazzeri et al., E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors, Oncogene, vol.26, pp.6927-6963, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00173067

D. Shweiki, A. Itin, D. Soffer, and E. Keshet, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis, Nature, vol.359, pp.843-848, 1992.

A. H. Varey, E. S. Rennel, Y. Qiu, H. S. Bevan, R. M. Perrin et al., VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy, Br J Cancer, vol.98, pp.1366-79, 2008.

J. Woolard, W. Y. Wang, H. S. Bevan, Y. Qiu, L. Morbidelli et al., , 2004.

, VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression, Cancer Res, vol.64, pp.7822-7857

L. Zhang, D. Yu, M. Hu, S. Xiong, A. Lang et al., Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression, Cancer Res, vol.60, pp.3655-61, 2000.